Nanoscale Iron Compounds Related to Neurodegenerative Disorders

Biomedical Nanostructures

Volumn , Issue , 2007, Pages 461-490

  Collingwood, Joanna F ^a   Dobson, Jon ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

Nanoscale iron compounds; Neurodegenerative disorders; Nonheme brain iron

Indexed keywords

EID: 47849085436     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470185834.ch18     Document Type: Chapter

References (161)

1. Harrison PM and Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996;1275:161-203.
2. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134-147.
3. Smith MA, Harris PLR, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 1997;94:9866-9868.
4. Ke Y and Qian Z. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2003;2:246-253.
5. Honda K, et al. Ribosomal RNA in Alzheimer disease is oxidized by bound redoxactive iron. J Biol Chem 2005;280:20978-20986.
6. Goodman L. Alzheimer's disease--a clinicopathologic analysis of 23 cases with a theory on pathogenesis. J Nerv Ment Dis 1953;118:97-130.
7. Gorell JM, et al. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995;45:1138-1143.
8. Dobson J. Nanoscale biogenic iron oxides and neurodegenerative disease. FEBS Lett 2001;496:1-5.
9. Dobson J. Magnetic iron compounds in neurological disorders. Ann N Y Acad Sci 2004;1012:183-192.
10. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004;5:863-873.
11. Schenck JF and Zimmerman EA. High-field magnetic resonance imaging of brain iron: birth of a biomarker? NMR Biomed 2004;17:433-445.
12. Haacke EM, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005;23:1-25.
13. Youdim MBH, Fridkin M, Zheng H. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J Neural Transm 2004;.1435-1463 (Online).
14. Bartzokis G, et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging 2007;28:414-423.
15. Pankhurst QA, Connolly J, Jones SJ, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D: Appl Phys 2003;36:R167-R181.
16. Douglas T, et al. Synthesis and structure of an iron(III) sulfide-ferritin bioinorganic nanocomposite. Science 1995;269:54-57.
17. Lieu P, Heiskala M, Peterson PA, Yang Y. The roles of iron in health and disease. Mol Aspects Med 2001;22:1-87.
18. Koeppen AH. A brief history of brain iron research. J Neurol Sci 2003;207: 95-97.
19. Zaleski SS. Das Eisen der Organe beim Morbus maculosus Werlhofii (The iron of the organs in Werlhof's morbus maculosus). Arch Exp Pathol Pharmakol 1886;23:77-90.
20. Connor JR. Iron acquisition and expression of iron regulatory proteins in the developing brain: manipulation by ethanol exposure, iron deprivation, and cellular dysfunction. Dev Neurosci 1994;16:233-247.
21. Gelman BB. Iron in CNS disease. J Neuropathol Exp Neurol 1995;54:477-486.
22. Hallgren B and Sourander P. The non-haemin iron in the cerebral cortexin Alzheimer's disease. J Neurochem 1958;3:41-51.
23. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P. A quantitative analysis of isoferritins in selected regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 1995;65:717-724.
24. Zecca L, et al. Iron, neuromelanin and ferritin in substantia nigra of normal subjects at different ages. Consequences for iron storage and neurodegenerative disorders. J Neurochem 2001;76:1766-1773.
25. Zecca L, et al. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 1996;73:407-415.
26. Kirschvink JL, Kobayashi-Kirschvink A, Woodford BJ. Magnetite biomineralization in the human brain. Proc Natl Acad Sci U S A 1992;89:7683-7687.
27. Schultheiss-Grassi PP, Wessiken R, Dobson J. TEM observation of biogenic magnetite extracted from the human hippocampus. Biochim Biophys Acta 1999; 1426:212-216.
28. Connor JR, Pavlick G, Karli D, Menzies SL, Palmer C. A histochemical study of iron-positive cells in the developing rat brain. J Comp Neurol 1995;355:111-123.
29. Gould RM, Freund CM, Palmer F, Feinstein DL. Messenger RNAs located in myelin sheath assembly sites. J Neurochem 2000;75:1834-1844.
30. Patino MM and Walden WE. Cloning of a functional cDNA for the rabbit ferritin mRNA repressor protein. J Biol Chem 1992;267:19011-19016.
31. Guo B, Yu Y, Leibold EA. Iron regulates cytoplasmic levels of a novel ironresponsive element binding protein without aconitase activity. J Biol Chem 1994;269:24252-24260.
32. Guo B, Brown FM, Phillips JD, Yu Y, Leibold EA. Characterization and expression of iron regulatory protein 2 (IRP2). J Biol Chem 1995;270:16529-16535.
33. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2006;2:406-414.
34. Koeppen AH, Dickson AC, Chu RC, Thach RE. The pathogenesis of superficial siderosis of the central nervous system. Ann Neurol 1993;34:646-653.
35. Harrison PM, Fischbach FA, Hoy TG, Haggis GH. Ferric oxyhydroxide core of ferritin. Nature 1967;216:1188-1190.
36. St Pierre TG, Webb J, Mann S. Ferritin and hemosiderin: structural and magnetic studies of the iron core. In: Mann S, Webb J, Williams RJP, editors. Biomineralization: Chemical and Biochemical Perspectives. Germany: Weinheim, VCH; 1989. p 295-344.
37. Massover W and Cowley J. Ultrastructure of ferritin macromolecules-lattice structure of core crystallites. Proc Natl Acad Sci U S A 1973;70:3847-3851.
38. Cowley JM, Janney DE, Gerkin RC, Buseck PR. The structure of ferritin cores determined by electron nanodiffraction. J Struct Biol 2000;13:210-216.
39. Quintana C, et al. Preliminary high resolution TEM and electron energy loss spectroscopy studies of ferritin cores extracted from brain in patients with neurodegenerative PSP and Alzheimer diseases. Cell Mol Biol 2000;46:807-820
40. Quintana C, Cowley JM, Marhic C. Electron diffraction and high-resolution electron microscopy studies of the structure and composition of physiological and pathological ferritin. J Struct Biol 2004;147:166-178.
41. Levi S, et al. Evidence that H- and L-chains have co-operative roles in the ironuptake mechanism of human ferritin. J Biochem 1992;65:710-716.
42. Chasteen ND and Harrison PM. Mineralization in ferritin: an efficient means of iron storage. J Struct Biol 1999;126:182-194.
43. Rohrer JS, et al. Stabilizaton of iron in a ferrous form by ferritin. J Biol Chem 1987;262:13385-13387.
44. Hilty S, Webb B, Frankel RB, Watt GD. Iron core formation in horse spleen ferritin: magnetic susceptibility, pH, and compositional studies. J Inorg Biochem 1994;56:173-185.
45. Collingwood JF, et al. In situ characterization and mapping of iron compounds in Alzheimer's tissue. J Alzheimer's Dis 2005;7:267-272.
46. Khan A, Dobson J, Exley C. The redox cycling of Fe(II) by Ab42. Free Rad Biol Med 2005;40:557.
47. Macara IG, Hov TG, Harrison PM. The formation of ferritin from apoferritin. Kinetics and mechanism of iron uptake. Biochem J 1972;126:151-162.
48. Powell AK. Ferritin. Its mineralization. In: Sigel A, Sigel H, editors. Iron Transport and Storage in Micro-Organisms, Plants, and Animals. New York: Marcel Dekker; 1998.p 515-561.
49. Frankel RB, Papaefthymiou GC, Watt GD. Variation of superparamagnetic properties with iron loading in mammalian ferritin. Hyperfine Interactions 1991; 66:71-82.
50. Zhao G, et al. Multiple pathways for mineral core formation in mammalian apoferritin: the role of hydrogen peroxide. Biochemistry 2003;42:3142-3150.
51. Prutkin L and Munro HN. Hemosiderin: nature, formation, and significance. Int Rev Exp Pathol 1980;22:193-225.
52. O'Connell M, et al. Formation of hydroxyl radicals in the presence of ferritin and haemosiderin: is haemosiderin formation a biological protective mechanism? Biochem J 1986;234:727-731.
53. Gossuin Y, et al. Looking for biogenic magnetite in brain ferritin using NMR relaxometry. NMR Biomed 2005;18:469-472.
54. Koeppen AH and Dentinger MP. Brain hemosiderin and superficial siderosis of the central nervous system. J Neuropathol Exp Neurol 1988;47:249-270.
55. Quintana C, et al. Study of the localization of iron, ferritin and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J Struct Biol 2006;153:42-54.
56. Dubiel SM, Zablotna-Rypien B, Mackey JB. Magnetic properties of human liver and brain ferritin. Eur Biophys J 1999;28:263-267.
57. Jellinger K, et al. Iron-melanin complexin substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 1992;59:1168-1171.
58. Collingwood JF and Dobson J. Mapping and characterization of iron compounds in Alzheimer's disease. J Alzheimers Dis 2006;10:215-222.
59. Hautot D, Pankhurst QA, Dobson J. Superconducting quantum interference device measurements of dilute magnetic materials in biological samples. Rev Sci Instrum 2005;76:045101.
60. Castelnau PA, et al. Abnormal iron deposition associated with lipid peroxidation in transgenic mice expressing interleukin-6 in the brain. J Neuropathol Exp Neurol 1998;57:268-282.
61. Mikhaylova A, et al. Detection, identification and mapping of iron anomalies in brain tissue using X-ray absorption spectroscopy. J R Soc Interface 2005;2:33-37.
62. Dobson J. Investigation of age-related variations in biogenic magnetite levels in the human hippocampus. Exp Brain Res 2002;144:122-126.
63. Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003;26:578-580.
64. Götz M, Double K, Gerlach M, Youdim MBH, Reiderer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 2004;1012:193-208.
65. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 1992;593:343-346.
66. Zecca L, et al. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett 2002;510:216-220.
67. Spatz H. Über den Eisennachweis in Gehirn, besonders in Zentren des extrapyramidal-motorischen Systems (On the visualization of iron in the brain, especially in the centers of the extrapyramidal motor system). Z Ges Neurol Psychiatr 1922;77:261-390.
68. Drayer B, et al. MRI of brain iron. AJR Am J Roentgenol 1986;147:103-110.
69. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ. Regional distribution of iron and iron-regulatory proteins in the brain in aging and disease. J Neurosci Res 1992;31:327-335.
70. Connor JR, Menzies SL, Burdo JR, Boyer PJ. Iron and iron management proteins in neurobiology. Pediatr Neurol 2001;25:118-129.
71. Connor JR, Boeshore KL, Benkovic SA. Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 1994;37:461-465.
72. Connor JR and Menzies SL. Cellular management of iron in the brain. J Neurol Sci 1995;134(Suppl):33-44.
73. Morris CM, Candy JM, Oakley AE, Bloxham CA, Edwardson JA. Histochemical distribution of non-haem iron in the human brain. Acta Anat Suppl (Basel) 1992;144:235-257.
74. Burdo JR and Conner JR. Brain iron uptake and homeostatic mechanisms: an overview. Biometals 2003;16:63-75.
75. Kaplan J and Kushner JP. Mining the genome for iron. Nature 2000;403:711-713
76. Wu LJ, et al. Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier. Brain Res 2004;1001:108-117.
77. Moos T, Trinder D, Morgan EH. Cellular distribution of ferric iron, ferritin, transferrin and divalent metal transporter 1 (DMT1) in substantia nigra and basal ganglia of normal and beta 2-microglobulin deficient mouse brain. Cell Mol Biol 2000;46:549-561.
78. Burdo JR, et al. Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J Neurosci Res 2001;66:1198-1207.
79. Focht SJ, et al. Regional distribution of iron, transferrin, ferritin and oxidatively modified proteins in young and aged Fischer 344 rat brains. Neuroscience 1997;79:255-261.
80. Connor JR, editor Metals and Oxidative Damage in Neurological Disorders. New York: Plenum Press; 1997.
81. Crichton RR, Ward RJ, Metal-Based Neurodegeneration: From Molecular Mechanisms To Therapeutic Strategies. Chichester; Hoboken, NJ: John Wiley Sons, Inc; 2006.
82. Curtis ARJ, et al. Mutations in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001;28:350-354.
83. Zhao G, Arosio P, Chasteen ND. Iron(II) and hydrogen peroxide detoxification by human H-chain ferritin. An EPR spin-trapping study. Biochemistry 2006; 45:3429-3436.
84. Morris CM, Kerwin JM, Edwardson JA. Non-haem iron histochemistry of the normal and Alzheimer's disease hippocampus. Neurodegeneration 1994; 3: 267-275
85. Zimmerman EA, Li Z, O'Keefe T, Schenck JF. High field strength (3 T) magnetic resonance imaging in Alzheimer's disease. Ann Neurol 2003;54(SUPPL 7):S68.
86. Nakata-Kudo Y, et al. Microbleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular disease. Dement Geriatr Cogn Disord 2006; 22: 8-14.
87. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 2004; 25: 5-18.
88. Rogers JT, et al. An iron-responsive element type II in the 50-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 2002; 277: 45518-45528.
89. Mantyh PW, et al. Aluminum, iron and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem 1993;61: 1171-1174.
90. House E, et al. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of A-42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J Alzheimers Dis 2004;6:291-301.
91. Khan A, Ashcroft AE, Higenell V, Korchazhkina OV, Exley C. Metals accelerate the formation and direct the structure of amyloid fibrils of NAC. J Inorg Biochem 2005;99:1920-1927.
92. Sayre LM, et al. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 2000;74:270-279.
93. Hautot D, Pankhurst QA, Khan N, Dobson J. Preliminary evaluation of nanoscale biogenic magnetite and Alzheimer's disease. Proc R Soc Lond B Biol Lett 2003;270:S62-S64.
94. Klintworth GK. Cerebral iron deposition in Huntington's disease. In:Barbeau A, Brunette JR, editors. Proceedings of the Second International Congress of Neurogenetics and Neuroophthalmology of the World Federation of Neurology; Excerpta Medica Foundation; Amsterdam: 1969. p 589-596.
95. Dexter DT, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-1975.
96. Bartzokis G, Cummings J, Perlman S, Hance DB, Mintz J. Increased basal ganglia iron levels in Huntington disease. Arch Neurol 1999;56:569-574.
97. Qian ZM and Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res Brain Res Rev 1998;27:257-267.
98. Hilditch-Maguire P, et al. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 2000;9:2789-2797.
99. Savoiardo M, Strada L, Oliva D, Girotti F, D'Incerti L. Abnormal MRI signal in the rigid form of Huntington's disease. J Neurol Neurosurg Psychiatry 1991;54: 888-891.
100. Bartzokis G and Tishler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntington's disease. Cell Mol Biol 2000;46: 821-834.
101. Reiderer P, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-520.
102. Oakley AE, et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease,Neurology .2007;68:1820-1825.
103. Kaur D and Andersen J. Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res Rev 2004;3:327-343.
104. Bartzokis G, Tishler TA, Shin IS, Lu PH, Cummings JL. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann N Y Acad Sci 2004;1012:224-236.
105. Costello DJ, Walsh SL, Harrington HJ, Walsh CH. Concurrent hereditary haemochromatosis and idiopathic Parkinson's disease: a case report series. J Neurol Neurosurg Psychiatry 2004;75:631-633.
106. Moos T and Morgan EH. The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann N Y Acad Sci 2004;1012:1012-1014.
107. Griffiths PD, Dobson BR, Jones GR, Clarke DT. Iron in the basal ganglia in Parkinson's disease--an in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 1999;122:667-673.
108. Hayflick SJ, Hartman M, Coryell J, Gitschier J, Rowley H. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 2006;27:1230-1233.
109. Zhou B, et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;4:345-349.
110. Harris ZL, Klomp LWJ, Gitlin JD. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr 1998;67(Suppl):972S-977S.
111. Cammermeyer J. Deposition of iron in paraventricular areas of the human brain in hemochromatosis. J Neuropathol Exp Neurol 1947;6:111-127.
112. McDougal DB and Adams RD. The neuropathological changes in hemochromatosis. J Neuropathol Exp Neurol 1950;9:117-118.
113. Morita H, et al. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol 1995;37:646-656.
114. Kawanami T, et al. Hereditary caeruloplasmin deficiency: clinicopathological study of a patient. J Neurol Neurosurg Psychiatr 1996;61:506-509.
115. Crompton DE, et al. Neuroferritinopathy: a window on the role of iron in neurodegeneration. Blood Cells Mol Dis 2002;29:522-531.
116. Vidal R, et al. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J Neuropathol Exp Neurol 2004;63:363-380.
117. Perez M, et al. Ferritin is associated with aberrant tau filaments present in progressive supranuclear palsy. Am. J Path 1998;152:1531-1539.
118. *and R2' in HIV-infected patients using the prime sequence as a measure of brain iron deposition. Magn Reson Imaging 1997;15:1113-1119.
119. Gelmann BB, et al. Siderotic cerebral macrophages in the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1992;116:509-516.
120. Butensky E, Kennedy CM, Lee MM, Harmatz P, Miaskowski C. Potential mechanisms for altered iron metabolism in human immunodeficiency virus disease. J Assoc Nurses AIDS Care 2004;15:31-45.
121. Puccio H and Koenig M. Recent advances in the molecular pathogenesis of Friedreich ataxia. Hum Mol Genet 2000;9:887-892.
122. Campuzano V, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-1427.
123. Waldvogel D, van Gelderen P, Hallett M. Increased iron in the dentate nucleus of patients with Friedreich's ataxia. Ann Neurol 1999;46:123-125.
124. Haba-Rubio J, et al. Restless legs syndrome and low brain iron levels in patients with haemochromatosis. J Neurol Neurosurg Psychiatry 2005;76:1009-1010.
125. Camaschella C. Understanding iron homeostasis through genetic analysis of haemochromatosis and related disorders. Blood 2005;106:3710-3717.
126. Nielsen JE, Jensen LN, Krabbe K. Hereditary hemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J Neurol Neurosurg Psychiatry 1995;59:318-321.
127. Berg D, et al. The basal ganglia in haemochromatosis. Neuroradiology 2000; 42: 9-13.
128. Connor JR, et al. Is hemochromatosis a risk factor for Alzheimer's disease? J Alzheimer's Dis 2001;3:471-477.
129. Moalem S, et al. Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet 2000;93:58-66.
130. Pulliam JF, et al. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am J Med Genet 119B:2003;48-53.
131. de Boer CB and Dekkers MJ. Thermomagnetic behaviour of haematite and goethite as a function of grain size in various non-saturating magnetic fields. Geophys J Int 1998;133:541-552.
132. Cranfield CG, et al. Biogenic magnetite in the nematode Caenorhabditis elegans. Proc R Soc Lond B 271:2004;S436-S439.
133. Till U, Timmel CR, Brocklehurst B, Hore PJ. The influence of very small magnetic fields on radical recombination reactions in the limit of slow recombination. Chem Phys Lett 1998;298:7-14.
134. Brooks RA, Vymaza J, Goldfarb RB, Bulte JWM, Aisen P. Relaxometry and magnetometry of ferritin. Magn Reson Med 1998;15:227-235.
135. Jensen PD. Evaluation of iron overload. Br J Haematol 2004;124:697-711.
136. Pan Y, et al. Electron beam damage studies of synthetic 6-line ferrihydrite and ferritin molecule cores within a human liver biopsy. Micron 2006;37:403-411
137. Perls M. Nachweis von Eisenoxyd in gewissen Pigmenten (Demonstration of iron oxide in certain pigments). Virchows Arch Pathol Anat Physiol Klin Med 1867;39:42-48.
138. Chwiej J, et al. Preparation of tissue samples for X-ray fluorescence microscopy. Spectrochim Acta B 2005;60:1531-1537.
139. Dobson J and Grassi P. Magnetic properties of human hippocampal tissue: evaluation of artefact and contamination sources. Brain Res Bull 1996;39: 255-259.
140. Watt F. Nuclear microscope analysis in Alzheimer's and Parkinson's disease: a review. Cell Mol Biol (Noisy-le-grand) 1996;42:17-26
141. Thiberge S, et al. Scanning electron microscopy of cells and tissues under fully hydrated conditions. PNAS 2004;101:3346-3351.
142. Dickson DPE, et al. Mössbauer spectroscopy, electron microscopy and electron diffraction studies of the iron cores in various human and animal haemosiderins. Biochim Biophys Acta--Protein Struct Mol Enzymol 1988;957:81-90.
143. Wade VJ, et al. Structure and composition of ferritin cores from pea seed. Biochim Biophys Acta 1993;1161:91-96.
144. Gossuin Y, Roch A, Bue FL, Muller RN, Gillis P. Nuclear magnetic relaxation dispersion of ferritin and ferritin like magnetic particle solutions: a pH-effect study. Magn Reson Med 2001;46:476-481.
145. Schenck JF. Magnetic resonance imaging of brain iron. J Neurol Sci 2003; 207:99-102.
146. Dedman DJ, et al. Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients. Biochem J 1992;287:509-514.
147. Vymazal J, Urgosik D, Bulte JW. Differentiation between haemosiderin and ferritin-bound brain iron using nuclear magnetic resonance and magnetic resonance imaging. Cell Mol Biol 2000;46:835-842.
148. Haque TL, et al. MR contrast of ferritin and haemosiderin in the brain: comparison among gradient-echo, conventional spin-echo and fast spin-echo sequences. Eur J Radiol 2003;48:230-236.
149. Porter JB, et al. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use. Ann N Y Acad Sci 2005; 1054:155-168.
150. Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 2002;23:1031-1038.
151. Liu G, et al. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 2006;406:189-193.
152. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65-81.
153. Cui ZR, et al. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur J Pharm Biopharm 2005;59:263-272.
154. Kaur D, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003;37: 899-909.
155. Richardson DR. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann N Y Acad Sci 2004;1012:326-341.
156. Bartzokis G, et al. MR evaluation of brain iron in young adults and older normal males. Magn Reson Imaging 1997;15:29-35.
157. Mayes EL, Mann S,Mineralization in nanostructured biocompartments: biomimetic ferritins for high density data storage. In:Niemeyer CM, Mirkin CA, editors. John Wiley Nanobiotechnology: Concepts, Applications and Perspectives. 2004. p 278-287.
158. St. Pierre TG, et al. Non-invasive measurement and imaging of tissue iron oxide nanoparticle concentrations in vivo using proton relaxometry. J Phys: Conf Ser 2005;17:122-126.
159. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006;58:1471-1504.
160. Bulte JW, Arbab AS, Douglas T, Frank JA. Preparation of magnetically labeled cells for cell tracking by magnetic resonance imaging. Methods Enzymol 2004; 386:275-299.
161. Daldrup-Link HE, et al. Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology 2003;228:760-767.